Literature DB >> 23204822

Atherosclerosis: current status of prevention and treatment.

Thomas F Whayne1.   

Abstract

The reality of regression of atherosclerotic plaques was established as long ago as 1987 by aggressive cholesterol reduction even before the era of statin therapy. Nevertheless, the most important aspect of patient benefit to prevent cardiovascular (CV) disease events is stabilization of these plaques so they will not rupture. Lowering of low-density lipoproteins is critical to this goal and can be considered the gold standard of preventive CV medicine. The major goal for the high-risk patient and the diabetic patient is lowering these harmful lipoproteins to less than 70 mg/dL. No discussion of CV disease prevention is complete without considering tobacco abuse and its elimination. Even secondhand smoke has been established as harmful. Control of hypertension is another major aspect of CV disease prevention, and a blood pressure less than 120/80 mm Hg is ideal. With obesity a major problem in the developed world, its role in the metabolic syndrome is of major significance as is the high prevalence of this so-called syndrome versus collection of specific risk factors in a population with poor health habits. Control of diabetes mellitus has established benefit from the standpoint of CV disease prevention except that some problems have been reported with extremely tight blood sugar control. Exercise was long considered good but now there are evidence-based reasons to recommend it as essential in CV disease prevention. There are many unforeseen frontiers in CV disease prevention but, for now, everything points to elevation of high-density lipoproteins as the next focus of this prevention.

Entities:  

Keywords:  Atherosclerosis; cholesterol; coronary heart disease; peripheral vascular disease; statins

Year:  2011        PMID: 23204822      PMCID: PMC3331649          DOI: 10.1055/s-0031-1295520

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  73 in total

1.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).

Authors:  Paul D Thompson; David Buchner; Ileana L Pina; Gary J Balady; Mark A Williams; Bess H Marcus; Kathy Berra; Steven N Blair; Fernando Costa; Barry Franklin; Gerald F Fletcher; Neil F Gordon; Russell R Pate; Beatriz L Rodriguez; Antronette K Yancey; Nanette K Wenger
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

2.  Effect of the Italian smoking ban on population rates of acute coronary events.

Authors:  Giulia Cesaroni; Francesco Forastiere; Nera Agabiti; Pasquale Valente; Piergiorgio Zuccaro; Carlo A Perucci
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

3.  Factors related to suddenness of death from coronary disease: combined Albany-Framingham studies.

Authors:  J T Doyle; W B Kannel; P M McNamara; P Quickenton; T Gordon
Journal:  Am J Cardiol       Date:  1976-06       Impact factor: 2.778

4.  Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial.

Authors:  Ramon Estruch; Miguel Angel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Valentina Ruiz-Gutiérrez; María Isabel Covas; Miguel Fiol; Enrique Gómez-Gracia; Mari Carmen López-Sabater; Ernest Vinyoles; Fernando Arós; Manuel Conde; Carlos Lahoz; José Lapetra; Guillermo Sáez; Emilio Ros
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

5.  The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.

Authors:  D H Blankenhorn; R L Johnson; S A Nessim; S P Azen; M E Sanmarco; R H Selzer
Journal:  Control Clin Trials       Date:  1987-12

6.  A nationally representative case-control study of smoking and death in India.

Authors:  Prabhat Jha; Binu Jacob; Vendhan Gajalakshmi; Prakash C Gupta; Neeraj Dhingra; Rajesh Kumar; Dhirendra N Sinha; Rajesh P Dikshit; Dillip K Parida; Rajeev Kamadod; Jillian Boreham; Richard Peto
Journal:  N Engl J Med       Date:  2008-02-13       Impact factor: 91.245

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.

Authors:  John F Paolini; Yale B Mitchel; Robert Reyes; Uma Kher; Eseng Lai; Douglas J Watson; Josephine M Norquist; Alan G Meehan; Harold E Bays; Michael Davidson; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2007-12-21       Impact factor: 2.778

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Benefits from treatment and control of patients with resistant hypertension.

Authors:  Michael Doumas; Vasilios Papademetriou; Stella Douma; Charles Faselis; Konstantinos Tsioufis; Eugene Gkaliagkousi; Konstantinos Petidis; Chrysanthos Zamboulis
Journal:  Int J Hypertens       Date:  2010-12-22       Impact factor: 2.420

View more
  10 in total

1.  Variations in Echogenicity in Carotid and Femoral Atherosclerotic Plaques with Pycnogenol + Centella Asiatica Supplementation.

Authors:  Gianni Belcaro; Umberto Cornelli
Journal:  Int J Angiol       Date:  2016-12-26

2.  Active matter therapeutics.

Authors:  Arijit Ghosh; Weinan Xu; Neha Gupta; David H Gracias
Journal:  Nano Today       Date:  2020-02-27       Impact factor: 20.722

Review 3.  Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases.

Authors:  William J Kelley; Hanieh Safari; Genesis Lopez-Cazares; Omolola Eniola-Adefeso
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-05-19

Review 4.  Lipophilic chemical exposure as a cause of cardiovascular disease.

Authors:  Harold I Zeliger
Journal:  Interdiscip Toxicol       Date:  2013-06

Review 5.  Exposure to lipophilic chemicals as a cause of neurological impairments, neurodevelopmental disorders and neurodegenerative diseases.

Authors:  Harold I Zeliger
Journal:  Interdiscip Toxicol       Date:  2013-09

Review 6.  Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations.

Authors:  Steven Mann; Christopher Beedie; Alfonso Jimenez
Journal:  Sports Med       Date:  2014-02       Impact factor: 11.136

7.  Impact of exercise intensity on oxidative stress and selected metabolic markers in young adults in Ghana.

Authors:  Patrick Diaba-Nuhoho; Emmanuel Kwaku Ofori; Henry Asare-Anane; Sylvester Yaw Oppong; Isaac Boamah; Dee Blackhurst
Journal:  BMC Res Notes       Date:  2018-09-03

Review 8.  Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy.

Authors:  Hamzah Khan; Omar Kanny; Muzammil H Syed; Mohammad Qadura
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

9.  Anti-inflammatory effects of a Chinese herbal medicine in atherosclerosis via estrogen receptor β mediating nitric oxide production and NF-κB suppression in endothelial cells.

Authors:  L Wang; X-M Qiu; Q Hao; D-J Li
Journal:  Cell Death Dis       Date:  2013-03-21       Impact factor: 8.469

10.  Association of Severity of Coronary Lesions with Bone Mineral Density in Postmenopausal Women.

Authors:  Rui Xu; Xin-Chun Cheng; Yuan Zhang; Hong-Mei Lai; Hong-Ni Yang
Journal:  Arq Bras Cardiol       Date:  2018-03       Impact factor: 2.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.